Results 141 to 150 of about 2,475,393 (270)

Discovery and Structure−Activity Relationships of Piperidinone- and Piperidine-Constrained Phenethylamines as Novel, Potent, and Selective Dipeptidyl Peptidase IV Inhibitors

open access: yes, 2016
Dipeptidyl peptidase IV (DPP4) inhibitors are emerging as a new class of therapeutic agents for the treatment of type 2 diabetes. They exert their beneficial effects by increasing the levels of active glucagon-like peptide-1 and glucose-dependent ...
Zhonghua Pei (1600639)   +13 more
core   +1 more source

Cardiorenal Mortality and Safety Outcomes of GLP‐1 Receptor Agonists in Type 2 Diabetes With BMI Below 27 kg/m2: A Target Trial Emulation

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10498-10512, November 2026.
ABSTRACT Aims Cardiorenal evidence for glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) derives mainly from trials in overweight or obesity; data in adults with Type 2 diabetes (T2D) and body mass index (BMI) below 27 kg/m2 are limited. Materials and Methods We emulated a target trial in the TriNetX US Collaborative Network (index dates 2020 to ...
Shao‐Chia Chen   +6 more
wiley   +1 more source

Exploratory Analysis of Type 2 Diabetes Mellitus Metabolic Phenotypes and Their Association With Vitamin D Status in Primary Care Patients

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10603-10614, November 2026.
ABSTRACT Aims This study aimed to perform an exploratory characterisation of metabolic phenotypes in primary care patients with type 2 diabetes mellitus (T2DM), using a predefined approach and examine their association with vitamin D status. Materials and Methods This cross‐sectional study included 178 participants randomly selected in Sergipe, Brazil.
Liliane Viana Pires   +10 more
wiley   +1 more source

Stacked ensemble learning and in-silico profiling reveal dual DPP-IV and SGLT2 inhibitors from Moringa oleifera metabolites

open access: yesScientific Reports
Diabetes mellitus (DM) is a growing global health challenge, particularly in low-resource settings where access to effective therapies remains limited. Dual inhibition of dipeptidyl peptidase IV (DPP-IV) and sodium–glucose co-transporter 2 (SGLT2) offers
M. K. Letuku   +4 more
doaj   +1 more source

Hitting Coronaviruses Where It Hurts: Antiviral Strategies Targeting Viral Proteins

open access: yesChemMedChem, Volume 21, Issue 19, 14 October 2026.
Viral proteins represent key vulnerabilities in human coronaviruses (HCoVs). This review outlines inhibitors targeting spike (S), main protease (Mpro), papain‐like protease (PLpro), and RNA‐dependent RNA polymerase (RdRp), mapping chemically diverse strategies that disrupt entry and replication, and provides an integrated view of current candidates ...
Álvaro de la Cruz‐Potenciano   +3 more
wiley   +1 more source

Integrated Transcriptomic and Physiological Analyses Reveal Disruption of Digestive Homeostasis Induced by Protease Inhibitors in Anticarsia gemmatalis Caterpillars

open access: yesArchives of Insect Biochemistry and Physiology, Volume 123, Issue 2, October 2026.
The peptides SKTI and GORE‐2 triggered distinct midgut responses in Anticarsia gemmatalis (Lepidoptera: Erebidae). SKTI promoted compensatory digestive and antioxidant responses, whereas GORE‐2 caused broader digestive protease repression, weaker antioxidant activation, and greater epithelial damage.
Neilier Rodrigues da Silva Júnior   +13 more
wiley   +1 more source

Extracellularly Activatable Conjugates of RGD Peptidomimetics and Cryptophycin for αVβ3‐Targeted Cancer Therapy

open access: yesChemistry – A European Journal, Volume 32, Issue 37, 1 October 2026.
Integrin αVβ3‐targeting small‐molecule drug conjugates (SMDCs) were synthesized by conjugating a cryptophycin payload through a neutrophil elastase‐cleavable NPV‐PABC linker. RGD peptidomimetic and linker epimers served as controls for targeting and enzymatic cleavage, and the resulting conjugates displayed subnanomolar cytotoxicity in vitro.
Dominic Seißenschmidt   +3 more
wiley   +1 more source

Review of sitagliptin phosphate: a novel treatment for type 2 diabetes

open access: yesVascular Health and Risk Management, 2007
Baptist GallwitzDept. Medicine IV, Eberhard Karls University, Tuebingen, GermanyAbstract: Sitagliptin (Januvia®, Merck Pharmaceuticals) is a dipeptidyl-peptidase inhibitor (DPP-4 inhibitor) that has recently been approved for the therapy of type 2 ...
Baptist Gallwitz
doaj  

Harnessing Terminalia arjuna in Next Generation Phytomedicine: Cutting Edge Nutraceutical Trends Shaping Food and Health

open access: yesFood Science &Nutrition, Volume 14, Issue 10, October 2026.
This graphical abstract illustrates the complete translational pipeline of Terminalia arjuna in modern phytomedicine and functional food development. It is rich in key bioactive compounds like arjunolic acid, arjungenin, flavonoids, and tannins which serve as the foundation for the plant's versatile medicinal uses and offers broad therapeutic benefits ...
Ishani Banerjee   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy